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ABSTRACT
Objectives: Verify the efficacy of clinical and morphologic parameters currently applied, including an immunohistochemical
panel, in the prognostic of prostate cancer, in specific stages of the disease.
Materials and Methods: In the period from 2002 to 2005, 40 surgical specimens were selected from patients submitted to
radical prostatectomy, with their respective diagnostic biopsies. Based on the pathological stage pT2 or pT3, the specimens
were separated into two groups, each one with 20 specimens. The results were confronted with pre- and postoperative
clinical data. Between the groups studied, the following was also analyzed: the profile of the expression of molecular markers
such as PSA, E-caderin, chromogranin-A, synaptofisin, P53 and Ki-67, both in the material coming from the prostatic biopsy
and from the surgical specimens of all patients.
Results: Data showed that patients with prostate-confined disease (pT2) presented lower PSA and Gleason score rates, in
relation to the group with extra-prostatic disease (pT3). Quantitative measures obtained for the percentage of positive
fragments from the biopsy revealed that patients from the pT2 group presented a lower mean percentage when compared to
the pT3 group. Positive margins of both groups influenced the need for complementary treatment before biochemical
progression. The comparison of the molecular marker expression in both stages was not significantly different.
Conclusion: It is evident the need to improve new methods, predominantly morphologic and molecular, that are able to further
exploit the study of the material from the prostatic biopsy. As to the profile of the molecular markers used in both studied
groups, there was no significant difference in the sense of outlining an additional prognostic factor in the clinical practice.
Key words: prostatic neoplasms; biopsy; prostatectomy; immunohistochemistry; pathology; prognosis
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INTRODUCTION
Prostate cancer is presented as the second
malignant disease most commonly diagnosed in men
aged more than 50 years and represents a social
problem with an important impact to men’s health, for
3% of the patients presenting this disease will die,
representing in the United States alone approximately
30,200 deaths per year (1).
Prostate cancer incidence presents regional
variations and according to the studies of Hsing et al.
(2), eastern countries present a lower incidence when
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compared to western countries. The improvement of
diagnostic methods associated to screening tests have
motivated the development of new ways to anticipate
the diagnosis, propose specific treatment, minimize
unnecessary treatments (3), and to reduce the high
percentage of post treatment biochemical recurrence
(4). However, it is important to consider that in patients
with normal prostatic digital rectal examination the
trend to reduce the PSA cut-off level (bellow 4 ng/
mL), could lead to the treatment of the so-called
insignificant tumors (5).
PSA levels, Gleason score and TNM staging
are established and considered essential to the prognostic
of prostate cancer, when analyzed separately or jointly
(6). Other factors such as the additional clinical-
morphologic ones and molecular markers can also
contribute substantially (7). Among the factors related
to the biopsy, the percentage of positive fragments has
presented a positive correlation with the potential risk
of biochemical progression after treatment (8).
Today, there is a big concern regarding the
research of new prognostic criteria with clinical
applicability that precisely define recurrence risk,
survival rate and the appropriate medical orientation,
for both clinical follow-up and active treatment. In
malignant neoplasia, there is a need to go beyond the
diagnosis and search information about the most
efficient prognostic and therapy for the disease (9).
Up to now, clinical factors have offered the basis to
build different nomograms that establish the risk and
the evolution of the disease. However, before the
variability of molecule expression in prostate cancer,
the molecular basis and protein expression are not
contemplated by these models (10).
The present study tried to assess in locally
confined disease (pT2) with extra-prostatic extension
(pT3), the efficiency of clinical and morphologic
parameters of prognostic presently applied in prostate
cancer, correlating them through immuno-
histochemistry, with proliferation indexes, cellular
adhesion and neuroendocrine differentiation.
MATERIALS AND METHODS
In the period from 2002 to 2005, 40 surgical
specimens from patients submitted to radical
prostatectomy were selected. When surgical indication
was given, all patients presented a clinical stage of
localized prostate cancer (T1c/T2c), according to
TNM staging system (11). Exclusion criteria involved
previous history of hormonal blockage and/or
radiotherapy, diagnosis based in material obtained from
transurethral resection of the prostate or any clinical
evidence of extra-prostatic or metastatic disease.
Selection of surgical specimens was based
on the pathological stages pT2 and pT3, which
respectively characterize a prostate-confined and
extra-prostatic disease. Twenty specimens were
selected from each group, being the first, pT2,
characterized by specimens from sub-stages pT2a (2
patients) and pT2c (18 patients), while the second was
formed by pT3a (16 patients) and pT3b (4 patients).
Mean patient’s age with pT2 was 62 years
and with pT3 was 65.5 years. After radical
prostatectomy, the patients were followed in an
outpatient clinic every 4 months, based on total PSA
serum concentration and for a mean time of 23 months.
Value equal or superior to 0.4 ng/mL was considered
as biochemical progression.
Prognostic parameters considered in the
preoperative period were age, digital rectal
examination, total PSA, free PSA, total of positive
fragments on biopsy, positivity percentage per
fragment and profile of molecular markers in the
prostatic biopsy material. All patients were
preoperatively submitted to pelvic computed
tomography and bone scintigraphy.
Surgical parameters included positive margins,
Gleason score, percentage of positive blocks,
pathological stage and molecular markers profile in
the surgical specimen.
Indication for ultrasound guided prostatic
biopsy, with a removal of an average of 15 fragments,
was due to alterations on serum PSA and/or on digital
rectal examination.
Biopsy fragments were embedded in paraffin,
sectioned and stained with hematoxylin and eosin.
Surgical specimens were analyzed by the same
pathologist were fixed, stained using India ink and
entirely processed by means of a previously established
topographic sequence. Characteristics of the surgical
specimen and the percentage of positive blocks offered
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the basis for staging and indirect calculation of the
tumor volume, according to the protocol of the College
of American Pathology (12), and of the American Joint
Commission on Cancer (2002) (13).
In the immunohistochemical evaluation, the
immunoperoxidase technique was used to identify the
PSA, Ki-67, p53, chromogranin-A, synaptofisin and
E-caderin.
The variables were analyzed by the
Kolmogorov-Smirnov test. Statistical tests applied to
compare two groups were t-Student for parametric
quantitative data and Mann-Whitney for the non-
parametric ones. Qualitative data were assessed by
the Fisher method and correlation between quantitative
data by the Spereman method. The analyses were
performed in the SigmaStat program (Jandel Scientific,
San Rafael, CA) and the graphics in the Microcal
Microcal Origin 6.0 (Microcal Software Inc.
1999). Values of p < 0.05 were considered statistically
significant.
RESULTS
In both the pre and postoperative phases of
the disease different clinical and morphological factors
in the same stage were studied and correlated as well
as between both stages studied (pT2 e pT3). The
results obtained in the preoperative phase for stage
pT2 (PSA, digital rectal examination, percentage of
positive fragments of the biopsy percentage of positivity
for the fragment and immunohistochemical study of
the biopsy) were studied and correlated to prognostic
factors (clinical/morphological) of the postoperative
phase, predominantly the data obtained from the
analysis of the surgical specimen. The same study
64 06.4 16.7 3+4 T1c 20.0 3+4 no no
53 07.4 50.0 4+3 T1c 87.5 3+4 no no
64 05.3 12.5 3+4 T2a 10.0 3+4 no no
62 05.9 25.0 3+5 T1c 63.3 3+4 yes no
62 05.0 50.0 3+6 T2b 34.0 4+3 yes yes
68 05.8 66.7 3+3 T1c 36.0 3+5 yes yes
59 05.1 33.3 4+3 T2b 20.0 3+4 no no
59 08.6 85.7 4+4 T2c 50.0 3+4 yes yes
65 04.8 33.3 3+3 T2b 16.7 3+4 no no
59 03.7 16.7 3+4 T1c 14.5 3+4 yes no
62 04.4 37.5 3+4 T2b 27.8 4+3 no no
67 08.4 25.0 3+5 T2b 09.7 4+3 no no
50 04.5 16.7 3+3 T1c 25.8 3+4 no no
66 05.1 08.7 3+3 T1c 24.4 3+5 no no
59 02.8 50.0 3+4 T2a 17.4 3+4 no no
45 06.4 16.7 3+3 T2a 32.9 3+4 yes no
75 20.0 25.0 3+4 T1c 70.0 3+4 no no
70 29.0 28.6 3+3 T2b 18.2 3+5 yes yes
68 03.8 33.3 3+4 T2b 26.3 3+4 no no

















Table 1 – Clinical and morphologic pre and postoperative data of the patients submitted to radical prostatectomy and
classified as pT2.
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was conducted for stage pT3. We present data from
the pre and postoperative phases pT2 (Table-1) and
pT3 (Table-2).
Preoperative Total PSA Serum Concentration
between the Groups
The first prognostic parameter assessed
isolatedly or together with other factors was
preoperative total PSA serum concentration. The PSA
study showed that patients that had a prostate-
confined disease (pT2) presented lower PSA rates
(7.5 ng/mL) in relation to the group presenting extra-
prostatic disease (pT3) (12.5 ng/mL) (p = 0.002; Mann-
Whitney).
Table 2 – Clinical and morphologic pre and postoperative data of the patients submitted to radical prostatectomy and
classified as pT3.
64 18.0 100.0 4+5 T1c 59.2 5+4 yes yes
69 13.7 033.3 3+5 T1c 34.9 4+3 yes yes
66 09.4 057.1 3+4 T2b 27.3 3+4 yes yes
68 27.0 057.1 4+3 T2b 51.8 3+4 no yes
73 08.0 058.3 4+3 T2b 41.4 4+3 yes no
70 06.1 028.6 3+5 T1c 33.9 4+3 yes yes
61 07.8 033.3 4+3 T1c 34.0 4+3 no no
73 06.6 033.3 4+5 T1c 26.3 4+3 no no
54 06.1 060.0 3+3 T1c 89.5 3+4 yes yes
71 23.0 066.7 5+3 T2b 87.2 3+5 yes yes
58 07.3 016.7 4+4 T1c 57.6 3+4 no no
73 09.3 066.7 3+4 T2c 79.4 3+4 yes yes
75 10.3 058.3 4+3 T1c 35.6 3+4 yes yes
69 19.0 028.6 4+3 T2c 73.9 3+4 yes yes
56 08.5 083.3 4+3 T2c 76.9 3+4 yes yes
65 08.8 008.3 3+3 T1c 23.4 3+5 no no
53 06.9 028.6 4+3 T2b 21.6 4+3 no yes
70 45.0 050.0 4+3 T2b 44.9 4+3 no no
63 02.5 066.7 4+4 T2c 47.1 4+3 yes yes


















For Gleason score of the biopsy, the results
revealed that patients from group pT2 presented
inferior mean values of Gleason when compared to
patients in pT3 group (p = 0.006; Mann-Whitney).
The comparison between the Gleason score
of the biopsy and the surgical specimen, within the
same group pT2 or pT3, showed a significant statistical
difference only for pT2 (p = 0.008; Mann-Whitney).
In pT2 group, 60% of the patients were sub-graduated,
i.e., the biopsy Gleason score was inferior to the one
of the surgical specimen, while for the pT3 group this
percentage was only 10%.
Gleason scores of the surgical specimen
between pT2 and pT3 groups were statistically similar
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(p > 0.05). It is worth to mention that in both the
predominant Gleason score was 3+4=7 or superior.
Positive Fragments of the Biopsy and Positive
Blocks of the Surgical Specimen
The study of the quantitative values obtained
for the percentage of positive fragments of the biopsy
showed that pT2 group patients presented an inferior
mean percentage (35.1%), when compared to pT3
group(49.3%) (p = 0.049; Mann-Whitney). A similar
result was obtained for the percentage of positive
blocks, indicating that the patients from pT2 group
presented an inferior tumor volume (32.9%) when
compared to pT3 (48.4%) (p = 0.015; Mann-Whitney).
Specific analysis for pT2 groups between the
percentage of positive fragments of the biopsy and
the percentage of positive blocks of the surgical
specimen, (r = 0.465; p = 0.0385; Spearman) or pT3
(r = 0.576; p = 0.007; Spearman), revealed a weak
positive correlation between both, demonstrating that
the two variables tend to increase jointly.
Biochemical Recurrence Associated To
Prostatic Parameters in Both Pre and
Postoperative Phases
Biochemical recurrence varied considerably
between pT2 and pT3 stages, being 20% and 70%,
respectively. The mean follow-up was of 22.8 months
for pT2 stage and 24.4 months for pT3 stage. Among
the prognostic parameters assessed the Gleason score
(superior to 7), positive surgical margins and tumor
volume, were associated to recurrence (Table-3).
The analysis of positive margins and
complementary treatment in pT2 or pT3 stages,
showed that the total positive margins of the surgical
specimen influenced the need for complementary
treatment, due to biochemical recurrence. For pT2
stage we have observed that, from the 7 patients with
positive margins, 4 of them presented biochemical
recurrence (p = 0.007; Fischer), while for pT3 this
relations was 13 positive margins with 12 recurrences
(p = 0.007; Fischer). Among the 14 recurrences, in
pT3 stage, 12 patients presented positive margins.
For the Gleason score parameter the patients
were grouped in two categories (7 < Gleason ≥ 7).
Among patients with a Gleason score equal or superior
to 7, at pT3 stage, 13 presented biochemical
recurrence.
In relation to tumor volume, the data show
that the patients that presented recurrence presented
also a higher tumoral volume (54.3% at pT3 stage).
P53 and Ki-67 Expression
The results for p53 and Ki-67 were expressed
in the percentage of labeled cells using the semi-
quantitative score method, based on the sum of the
immunopositive tumor cells proportion and the intensity
of the immunolabelling expression. On Tables-4 and
     With Recurrence (number)         Without Recurrence (number)
Variables pT2 pT3 pT2 pT3
Positive margin 04 12 03 02
Negative margin 00 02 13 05
PSA < 10 ng/mL 03 08 15 05
PSA > 10 ng/mL 01 06 01 01
Gleason < 7 02 01 06 01
Gleason > 7 02 13 10 05
Estimated tumor volume (%) 34.5 54.3 32.5 37.9
Table 3 – Clinical and morphologic variables associated to postoperative recurrence.
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5, the uniform expression patterns are presented,
independently from the stage (pT2 and pT3), both in
the biopsy and in the surgical specimen.
Expression of Chromogranin-A and Synaptofisin
The expression of the immunomarkers,
chromogranin-A and synaptofisin utilized to
differentiate neuroendocrine cells was assessed
qualitatively and classified as absent, light, moderate,
intense and very intense. The results are presented
on Tables-6 and 7, for the different categories. A
significant expression of these markers was observed,
except in patients with compromised seminal vesicles.
E-caderin Expression
E-caderin was assessed both qualitatively and
quantitatively with the respective expression forms
(Figure-1). The results obtained showed a variability
of the immunomarker. In most of the tissues assessed,
including biopsies and surgical specimens,
independently from the stage, the e-caderin expression
was absent or the cytoplasmic pattern was
predominant (Table-8). The usual membrane labeling,
identified in normal epithelium, was rarely observed.
PSA Expression
The PSA molecular labeling presented a very
intense expression with cytoplasmic granular pattern
in all tissues from biopsies and from surgical specimens
in pT3 stage.
Molecular Markers and Recurrence
For a global analysis between the recurrence
of the disease and the profile of various molecular
markers used, it was not possible to establish a
correlation between these parameters. The expression
of the molecular markers was similar for patients with
or without recurrence.
Table 4 – Number of patients that present p53 nuclear expression in the biopsy and in the surgical specimen, in stages
(pT2 and pT3). The columns refer to the percentage of cells with expression.
Stage 0 to 5 6 to 10 11 to 20 > 20
pT2 biopsy 12 3 3 2
pT2 specimen 20 0 0 0
pT3 biopsy 18 1 0 1
pT3 specimen 18 2 0 0
Table 5 – Number of patients that present Ki-67 nuclear expression in the biopsy and in the surgical specimen, in stages
(pT2 and pT3). The columns refer to the percentage of cells with expression.
Stage 0 to 5 6 to 10 11 to 20 > 20
pT2 biopsy 18 2 0 0
pT2 specimen 20 0 0 0
pT3 biopsy 17 2 1 0
pT3 specimen 18 0 2 0
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Table 6 – Number of patients grouped in the different categories, based on the chromogranin-A expression in both stages
(pT2 and pT3).
Stage Absent Light Moderate Intense Very Intense
pT2 biopsy 12 4 2 1 0
pT2 specimen 18 0 1 1 0
pT3 biopsy 11 5 4 0 0
pT3 specimen 14 4 2 0 0
Table 7 – Number of patients grouped in the different categories, based on the synaptofisin expression in both stages (pT2
and pT3).
Stage Absent Light Moderate Intense Very Intense
pT2 biopsy 03 15 1 1 0
pT2 specimen 18 00 2 0 0
pT3 biopsy 14 04 1 1 0
pT3 specimen 15 05 0 0 0
COMMENTS
The present work reinforces the importance
of the prognostic parameters already consolidated in
nomograms and exhaustively studied in large
populations (14). However, the present sample
suggests a late diagnosis when we aim at the cure by
means of only one form of treatment, confirmed by
the high tumor recurrence rate or residual disease in
pT3 group.
Mean PSA in pT2 group of 7.5 ng/mL was
divergent from the 12.5 ng/mL found for pT3 group.
We have observed in both groups a higher levels of
PSA, when compared to the cuff of values considered
nowadays (16,17).
Total-PSA serum concentration can be
altered due to many factors, among which the
patient’s age and the prostate volume and cannot be
considered isolatedly for tumor diagnosis. However,
there are evidences that in a population with normal
digital rectal examination and PSA between 0 and 4
ng/mL, 15.2% present prostate cancer detected in
the biopsy (18).
Gleason score has consolidated its importance
as one of the most important prognostic factors in both
pre and postoperative phases. A fact that deserves
attention in the present sample is the trend to
undergraduate the Gleason score in prostatic biopsy
material, when compared to the Gleason score of the
surgical specimen. An explanation, among other
Table 8 – Number of patients grouped in the different
categories, based on the E-caderin expression in both
stages (pT2 and pT3).
Stage Absent Cytoplasmic Membrane
pT2 biopsy 9 7 4
pT2 specimen 10 7 3
pT3 biopsy 14 5 1
pT3 specimen 16 4 0
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variables, is that the limited sampling and the quality
of the biopsy material, mainly when in phases where
the disease is localized is represented by a small tumor
volume. A growing tendency of the Gleason score was
verified in pT3 group, confirming the correlation
between the increases of the Gleason score with the
worst prognostic (19).
Medial results obtained for the percentage of
positive fragments reflected a difference in the
extension of the tumor between the groups analyzed,
being lower in pT2. Gancarczyk et al. showed this
parameter to be of great relevance, mainly when
associated to pre-treatment PSA and the higher
Gleason score of the biopsy, suggesting to be a
predictive factor of the pathological staging (20).
A B
C D
Figure 1 – Prostatic tumor with expression of different immunomarkers. A) Variation in the E-caderin expression, with focal membrane
labeling and cytoplasmic pattern. B) Cytoplasmic expression of E-caderin with loss of membrane expression. C) Neuroendocrine
differentiation with positivity for chromogranin-A. D) Strong nuclear expression for p-53.
The results obtained for immunolabelling
related to cellular proliferation, demonstrated a similar
standard expression of p53 and Ki-67 in the biopsy
and in the surgical specimen when both stages are
compared.
The studies of Downing et al. (21) showed a
significant association between the nuclear expression
of mutant p53 and a higher risk of recurrence, or a
lower disease-free survival. The p53 gene mutation
blocks apoptosis induction (22). In this work, cellular
proliferation markers, in prostatic biopsy, do not
influence the prognostic factors related to the
recurrence of the disease and compromised margins.
Neuroendocrine cells, usually positive for
chromogranin-A are found sparsely in the prostatic
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tissue. This quantity can be increased or suffer
changes, originating neuro-hormonal stimulations to the
tumor microenvironment. Neuroendocrine
differentiation in specimens from radical
prostatectomies associated to the recurrence of the
disease is still an open subject in literature. Some
authors found a correlation (23), while others did not
obtain the same results (24). Neuroendocrine cells are
prominent in only 5 to 10% of the adenocarcinomas,
having an important correlation with tumors presenting
advanced stages. In gland-confined tumors, its
expression does not correlate to the stage of the
disease but with the Gleason score (25).
In the present study based on neuroendocrine
cell immunomarkers chromogranin-A and synaptofisin,
it was observed that in larger volume tumors with
compromised seminal vesicle, there was a larger
distinct expression or these markers, in two ways. It
was observed a neuroendocrine differentiation of
tumor cells and also a neuroendocrine cell hyperplasia
in the normal tissue.
The PSA expression in pT3 stage was
homogeneous and intense with cytoplasmic granular
pattern in tissues from biopsies and surgical specimens.
It was observed a lower coincident expression with
tumors that presented a high Gleason score.
Immunohistochemistry applied to PSA presents
limitations, because the expression is observed in
normal and neoplastic cells, showing that there is no
correlation between serum concentration of this
antigen and the intensity immunoreactivity of tissue.
Immunohistochemistry for this marker can be useful
as a method to assess its expression profile all through
treatment (26).
The lack of E-caderin expression in the plasma
membrane was observed in pT2 and pT3, with a
percentage of 30 and 50% respectively. The lack of
E-caderin expression relates to the advanced stage
of the disease and metastasis. It is important to highlight
that in certain metastatic tumors the E-caderin can
return to its membrane expression. This finding
remains without any clarification (27,28). The lack of
E-caderin expression is being related to a high Gleason
score, according to the work of Wu et al. (29).
The immunolabelling profile in the present
work cannot establish correlations of expressive
differences for immunomarkers with neuroendocrine
cell expressions and cell proliferation indicators.
However, in relation to E-caderin, it was observed
lack of expression related to the tumor tissue.
Positive margins with or without post radical
prostatectomy extra-prostatic extension has been
suffering a wide percentage variation as the medical
literature registers (31). Basic influences that origin
positive margins reside in the more or less rigorous
criteria of selecting the surgical patient and in the
surgical strategy utilized.
We have observed in our results a higher
incidence of recurrence in the cases with positive
surgical margins. All patients of pT2 group with
recurrence of the disease presented positive peripheral
surgical margins, demonstrating the importance of this
parameter mainly in stages that characterize a localized
disease. Positive margins in pT2 (35%) and pT3 (65%)
groups should warn, based on the consolidated
prognostic factors, changes in the surgical strategy
(32). Positive surgical margin is represented by the
tumor that reaches the previously stained surgical
specimen surface, independently from having or not
extra-prostatic extension.
When comparing the mean time of biochemical
recurrence between both groups it is evident the
negative impact originated by the presence of positive
margins in pT3 group, predicting the need for
complementary treatment in a disease with a worst
prognostic. Also, in pT3 group, 20% of the patients
presented positive seminal vesicle. Even though there
has not been observed any preoperative risk factor
suggesting this condition, prognostic factors such as
PSA, histological grade and percentage of positive
fragments in the biopsy, have been correlated with
seminal vesicles involvement (33).
In our sample, among the 20 patients with pT2
disease, none was identified with pT2b, reinforcing
the difficulty of classifying such stage based on the
surgical specimen (34).
It is worth to highlight that the 7 patients with
positive margins and in the pT2 group did not present
safe tissue parameters to evaluate the possibility of
extra-prostatic extension. Thus, it remains the
possibility that these patients were under staged and
are in truth pT3.
671
Morphologic and Clinical Parameters in pT2 - pT3 Prostate Cancer
It is evident the need to improve new
methods, predominantly morphologic and molecular,
that are able to further exploit the study of the
material from the prostatic biopsy. As to the profile
of the molecular markers used in both studied groups,
there was no significant difference in the sense of
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